Pfizer earnings top estimates on higher sales
Pfizer reported better-than-expected second-quarter earnings due to solid sales of several pharma products that offset the hit from the strong dollar.
Net income fell 23.1 percent from the year-ago period to US$2 billion. Sales rose 10.9pc to $13.1 billion. However, costs in several categories rose. Leading drugs that helped boost performance included the breast cancer drug Ibrance, the blood clot drug Eliquis and Lyrica, which treats pain.